research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
=== Other guidance === Because nanotechnology is a recent development, the health and safety effects of exposures to nanomaterials, and what levels of exposure may be acceptable, are subjects of ongoing research. Of the possible hazards, inhalation exposure appears to present the most concern. Animal studies indicate that carbon nanotubes and carbon nanofibers can cause pulmonary effects including inflammation, granulomas, and pulmonary fibrosis, which were of similar or greater potency when compared with other known fibrogenic materials such as silica, asbestos, and ultrafine carbon black. Acute inhalation exposure of healthy animals to biodegradable inorganic nanomaterials have not demonstrated significant toxicity effects. Although the extent to which animal data may predict clinically significant lung effects in workers is not known, the toxicity seen in the short-term animal studies indicate a need for protective action for workers exposed to these nanomaterials, although no reports of actual adverse health effects in workers using or producing these nanomaterials were known as of 2013. Additional concerns include skin contact and ingestion exposure, and dust explosion hazards. Elimination and substitution are the most desirable approaches to hazard control.
In contrast, on the same day Medtronic's capitalization was listed on Bloomberg at just over $130 billion (or €115 billion). Medtronic's acquisition of Covidien made Medtronic the world's largest medical device company by revenues.
In early 1983, Carrey decided to move to Hollywood where he began regularly performing at The Comedy Store. Getting on The Tonight Show became his immediate career goal, and, by spring 1983, he appeared to have achieved it after getting booked for a stand-up set on the highly-rated late night show. However, a lukewarm club set at The Improv got him unbooked. Though struggling to replicate his success in Los Angeles, Carrey continued being a big hit in his hometown Toronto where he returned during late April 1983 to perform at the short-lived B.B. Magoon's theatrical venue on Bloor Street on three consecutive nights. While in town, CTV's flagship newsmagazine program W5 did a feature on Carrey that aired nationally in Canada. Back in L.A., within months, he landed the main role on The Duck Factory, a sitcom being developed for NBC, and, in late November 1983, still got to debut his impressionist act on The Tonight Show Starring Johnny Carson via a promotional appearance for the sitcom about to start airing nationally in the United States on the same network. In the meantime, he was cast for a supporting role in the Warner Bros. comedy production Finders Keepers, shot in the Canadian province of Alberta during late summer 1983. For his Tonight Show appearance that aired on American Thanksgiving, 21-year-old Carrey went through his most popular impressions—Elvis Presley, Leonid Brezhnev, Jack Nicholson, Bruce Dern, Clint Eastwood, Charles Bronson, Michael Landon, James Dean, E.T.
== Categories == The two basic categories used to classify fish protein powders are dependent on the levels of protein, fat, mineral and carbohydrate contained in the powder. The minerals are mostly naturally occurring, organic complexes of magnesium, calcium and phosphorus. The spray drying process may utilize other minerals and carbohydrates to improve flow characteristics of the final product thus altering the natural balance. Powders will all have a residual moisture content in the 4-8% range.
junk RNA Any RNA-encoded sequence, especially a transcript, that appears to have no known biological function, or whose function has no positive or a net negative effect on the fitness of the genome from which it is transcribed. Despite remaining untranslated, many non-coding RNAs still serve important functions, whereas junk RNAs are truly useless: often they are the product of accidental transcription of a junk DNA sequence, or they may result from post-transcriptional processing of primary transcripts, as with spliced-out introns. Junk RNA is usually quickly degraded by ribonucleases and other cytoplasmic enzymes.
Sources: en.wikipedia.org
== Cambodian controversy (1970) == The Paris peace talks had become stalemated by late 1969, owing to the obstructionism of the South Vietnamese delegation who wanted the talks to fail. The South Vietnamese President Nguyễn Văn Thiệu did not want the United States to withdraw from Vietnam, and out of frustration with him, Kissinger decided to begin secret peace talks in Paris parallel to the official talks that the South Vietnamese were unaware of. On 21 February 1970, in a modest house in a Paris suburb, Kissinger secretly met Lê Đức Thọ, the North Vietnamese diplomat who was to become his most tenacious adversary. In 1981, Kissinger told the journalist Stanley Karnow: "I don't look back on our meetings with any great joy, yet he was a person of substance and discipline who defended the position he represented with dedication". Not until February 1971 were Rogers and Laird first informed of the parallel peace talks in Paris. Kissinger was to meet Tho three times between February–April 1970, and the North Vietnamese first sensed a softening of the American position during these talks as Kissinger slightly altered the "mutual withdrawal formula" that the Americans had previously held to. Nixon was gravely disappointed that the secret talks in Paris did not have the prompt results he wanted. Kissinger wrote in his memoirs that "historians rarely do justice to the psychological stress on a policy-maker", noting that by early 1970 Nixon was feeling very much besieged and inclined to lash out against a world he was believed was plotting his downfall.
== Reasons == Within anthropology, the study of the body as a boundary has been long debated. In 1909, Van Gennep described bodily transformations, including tattooing, scarification, and painting, as rites of passage. In 1963, Lévi-Strauss described the body as a surface waiting for the imprintation of culture. Turner (1980) first used the term "social skin" in his detailed discussion of how Kayapo culture was constructed and expressed through individual bodies. Inscribed skin highlights an issue that has been central to anthropology since its inception: the question of boundaries between the individual and society, between societies, and between representation and experiences.
=== Initial appearance === The first known documented instance of an attack by the Phylloxera in France was in the village of Pujaut in the department of Gard of the former province of Languedoc, in 1863. The wine makers there did not notice the aphids, just as the French colonists in America had not, but they noted the mysterious blight that was damaging their vines. The only description of the disease that was given by these wine growers was that it "reminded them distressingly of 'consumption'"(tuberculosis). The blight quickly spread throughout France, but it was several years before the cause of the disease was determined.
=== August === 1 August Nationwide reports that house prices fell by 3.8% in July, the sharpest decline since July 2009. The UK's first permanent drone delivery service begins, with Royal Mail and Skyports establishing a daily inter-island mail distribution between three islands on Orkney. Changes on excise duty for alcohol come into force, with the tax levied depending on a drink's strength. Former SNP MP Margaret Ferrier loses her seat, following a successful recall petition, triggering a by-election. 2 August – COVID-19 in the UK: The UK Health Security Agency reports the spread of a new variant known as EG.5.1. 3 August The National Risk Register publishes its latest report on future threats facing the UK. It puts the chance of another pandemic at between 5% and 25%. Other risks include extreme weather caused by worsening climate change, advances in artificial intelligence (AI) systems, terrorism such as cyberattacks on infrastructure, and the assassination of public figures. Greenpeace activists climb onto the roof of Rishi Sunak's North Yorkshire home, unfurling sheets of black fabric, in protest at his recent decision to expand oil and gas production in the North Sea. The Bank of England raises its baseline interest rate from 5% to 5.25%, the 14th consecutive increase and the highest level since April 2008. The Bank also predicts inflation to fall below 5% in the final quarter of 2023. Brexit: Checks on fresh food from the EU are delayed for a fifth time, amid concerns over red tape.
Recent advancements in bioorthogonal chemistry have revealed applications in protein analysis. The extension of using organic molecules to observe their reaction with proteins reveals extensive methods to tag them. Unnatural amino acids and various functional groups represent new growing technologies in proteomics. Specific biomolecules that are capable of being metabolized in cells or tissues are inserted into proteins or glycans. The molecule will have an affinity tag, modifying the protein allowing it to be detected. Azidohomoalanine (AHA) utilizes this affinity tag via incorporation with Met-t-RNA synthetase to incorporate into proteins. This has allowed AHA to assist in determine the identity of newly synthesized proteins created in response to perturbations and to identify proteins secreted by cells. Recent studies using ketones and aldehydes condensations show that they are best suited for in vitro or cell surface labeling. However, using ketones and aldehydes as bioorthogonal reporters revealed slow kinetics indicating that while effective for labeling, the concentration must be high. Certain proteins can be detected via their reactivity to azide groups. Non-proteinogenic amino acids can bear azide groups which react with phosphines in Staudinger ligations. This reaction has already been used to label other biomolecules in living cells and animals. The bioorthogonal field is expanding and is driving further applications within proteomics. It is worthwhile noting the limitations and benefits.
Sources: en.wikipedia.org
Richard Küch (1860-1915) was able to melt quartz glass - the basis for UV radiation sources - for the first time in 1890 and founded the Heraeus Quarzschmelze. He developed the first quartz lamp (sun lamp) for generating UV radiation in 1904, thus laying the foundation for this form of light therapy. Despite the dosage problems, doctors increasingly used quartz lamps in the early 20th century. Internal medicine specialists and dermatologists were among the most eager testers. After successful treatment of skin tuberculosis, internal medicine began to treat tuberculous pleurisy, glandular tuberculosis and intestinal tuberculosis. In addition, doctors tested the effect of quartz lamps on other infectious diseases such as syphilis, metabolic diseases, cardiovascular diseases, nerve pain such as sciatica, or nervous diseases such as neurasthenia and hysteria. In dermatology, fungal diseases, ulcers and wounds, psoriasis, acne, freckles and hair loss were also treated with quartz lamps, while in gynecology, abdominal diseases were treated with quartz lamps. Rejuvenation specialists used artificial high-altitude sunlight to stimulate gonadal activity and treated infertility, impotentia generandi (inability to conceive), and lack of sexual desire by irradiating the genitals. For this purpose, Philipp Keller (1891-1973) developed an erythema dosimeter with which he measured the amount of radiation not in Finsen units (UV radiation with a wavelength λ of 296.7 nm and an irradiance E of 10−5 W/m2), but in height solar units (HSE).
== Chemical synthesis == N-Acyl dehydroalanine derivatives have been synthesized by dehydration of serines using a tert-butoxycarbonate leaving group, or by conversion of Cysteine derivatives using various reagents for the elimination of the Thiol-group. Various protected dehydroamino acids can be produced by electrochemical oxidation of the respective amino acid derivative in methanol. Dehydroalanine derivatives have proven to be useful in late-stage peptide modification, enabling straightforward synthesis of functionally diverse peptides or proteins.
=== Pharmacodynamics === Unlike benzodiazepines, etifoxine may produce its anxiolytic effects through a dual mechanism, by directly binding to GABAA receptors and (purportedly, exact binding site undetermined) to the mitochondrial translocator protein (TSPO). This results in stimulation of the biosynthesis of endogenous neurosteroids, for instance allopregnanolone, a highly potent GABAA receptor positive allosteric modulator. At GABAA receptors etifoxine binds at the α+β− interface and preferentially potentiates α2β3γ2 and α3β3γ2 receptor types. This direct allosteric potentiation can only be observed at relatively high concentrations (starting at >1 mM) and is perhaps not physiologically relevant at normal human doses. This is different from benzodiazepines and etifoxine can be used alongside benzodiazepines to potentiate their effects without competing for binding sites; however, it also means that the direct effects of etifoxine are not reversed by the benzodiazepine antagonist flumazenil.
Ceftolozane/tazobactam, sold under the brand name Zerbaxa, (Merck) is a fixed-dose combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia. The most common side effects include nausea (feeling sick), headache, constipation, diarrhea and fever. Ceftolozane is a type of antibiotic called a cephalosporin, which belongs to the wider group of antibiotics called beta-lactams. It works by interfering with the production of molecules that bacteria need to build their protective cell walls. This causes weakness in the bacterial cell walls which then become prone to collapse, ultimately leading to the death of the bacteria. Tazobactam blocks the action of bacterial enzymes called beta-lactamases. These enzymes enable bacteria to break down beta-lactam antibiotics like ceftolozane, making the bacteria resistant to the antibiotic's action. By blocking the action of these enzymes, tazobactam allows ceftolozane to act against bacteria that would otherwise be resistant to ceftolozane. Ceftolozane is combined with the β-lactamase inhibitor tazobactam, which protects ceftolozane from degradation. It was approved for medical use in the United States in December 2014, and in the European Union in September 2015.
==== Insurance ==== The transgender population has faced an increased burden of disease due to the lack of gender affirming coverage by insurance. Compared to the cisgender population, the transgender community has a lower insurance rate and faces obstacles with insurance (both private and public) denying coverage for many of their healthcare needs. According to the United States Transgender Survey (USTC), 20% of the transgender community reported insurance coverage for gender affirming care being partially covered or not being covered at all. Without insurance coverage, the transgender community is left with numerous out of pocket costs. The lack of insurance coverage denies these patients their healthcare needs and creates financial insecurity. These challenges with insurance create a decrease in healthcare outreach by the transgender community due to the costs. According to the United States Transgender Survey (USTS), 37.6% of the transgender community reported missing or avoiding preventative screenings and healthcare visits due to the costs This creates an increased burden of disease, and statistics show a higher rate of mental health conditions, poor physical health, and respiratory conditions, such as asthma. Besides the toll on this community's health and financial stability, insurers also refuse to change their records to reflect the true nature of the patient. Many health insurance companies have refused to change the individual's name and gender on their records. This creates another obstacle for this community to receive care while feeling accepted.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.